1 hour agoBusiness
35LENS
2 SourcesGurgaon, India
thebalanced.newsEli Lilly's Mounjaro Surpasses Merck's Keytruda as Top-Selling Drug Globally
Eli Lilly's diabetes and obesity drug Mounjaro has become the world's best-selling medication, generating $8.7 billion in the first quarter of 2026 and surpassing Merck's cancer therapy Keytruda, which earned $7.9 billion. Mounjaro and Lilly's weight-loss drug Zepbound, both containing tirzepatide, collectively earned $36.5 billion in 2025, outpacing Keytruda's $31.6 billion. This shift highlights growing global demand for metabolic treatments amid rising obesity and diabetes rates, with Mounjaro also leading sales in India since its 2025 launch.
Political Bias
0%100%0%
Sentiment
72%
AI Analysis
Political bias across 2 sources
● Left 0%● Center 100%● Right 0%
The articles primarily present a commercial and medical perspective on pharmaceutical sales without evident political framing. They focus on industry developments, market data, and health trends, representing viewpoints from analysts and industry experts. There is no partisan or ideological bias, as coverage centers on factual sales figures and market shifts in diabetes and cancer treatments.
Sentiment — Positive (72/100)
The tone across the articles is generally positive and neutral, emphasizing Mounjaro's commercial success and its impact on global health markets. The coverage highlights the drug's effectiveness and growing demand without sensationalism or criticism. While noting Keytruda's previous leadership, the sentiment remains factual and balanced, reflecting industry evolution rather than controversy.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.
| Source | Their headline | Bias | Sentiment |
|---|---|---|---|
| indiatoday | Mounjaro overtakes blockbuster cancer therapy Keytruda to become world's best-selling drug | Center | Positive |
| businessstandard | Eli Lilly's Mounjaro overtakes Merck's Keytruda as world's top-selling drug | Center | Positive |
Coverage timeline
businessstandard broke this story on 7 May, 02:39 am. Other outlets followed.
- 1businessstandard7 May, 02:39 amEli Lilly's Mounjaro overtakes Merck's Keytruda as world's top-selling drug
- 2indiatoday7 May, 08:27 amMounjaro overtakes blockbuster cancer therapy Keytruda to become world's best-selling drug
Lens Score breakdown
35/100
Public interest0/100
Coverage gap100%
Story is receiving appropriate media attention relative to public interest.
Who's involved
Institutions and figures named across source coverage.
Corporate
Eli LillyEli Lilly Co.Novo NordiskMerck Co.AbbVie Inc.BMO Capital Markets CorpMerck CoNovo Nordisk A S
Story context
- Category
- Business
- Location
- Gurgaon, India
- Sources analysed
- 2
- Last analysed
- 7 May 2026
- Key entities
- SemaglutideMedicationMerck & Co.PembrolizumabTirzepatideDiabetesAdalimumabNovo NordiskCancerGlucagon-like peptide-1Active ingredientObesity
Related Coverage
Select a news story to see related coverage from other media outlets.